



Joint Chemical Probe

USP21 Inhibitor
BAY-805




September 21, 2022

Presenter:

Fabian Göricke

on behalf of the team





USP21 Probe BAY-805


Scientific Rationale

USP21 = ubiquitin-specific-processing protease 21

- 62 kDa, Gene ID: 27005
- ubiquitously expressed on mRNA level
- USP21 cleaves **K48-ubiquitin (degradation)**, and **mono-Ubiquitin**, **K11-**, **K63-**, **K29** and **linear diUbiquitin**
- **Cysteine 221 is essential for catalytic activity** and function
- **Several SMOL binding modes expected** (displacing either ubiquitin or protein substrates)

Mode of action:

- **Several substrates have been described, e.g. in the field of immune response and cancer cell growth**
- **USP21 deubiquitinates and inactivates STING** in an enzymatic activity-dependent matter
- USP21 inhibits tumor necrosis factor alpha-induced **NFκB activation** via binding to and deubiquitinating receptor-interacting protein 1 (**RIP1**)





Model based on X-rays of USP21 + Ubi, USP7 and USP2: Ernst et al., Science 2013, 339, 590; Turnbull et al., Nature 2017, 550, 481; Kategaya et al., Nature 2017, 550, 534; Chuang et al. Sci. Rep. 2018, 8, 3102.





USP21 Probe BAY-805


Discovery and Biochemical Activity



Biochemical activity:



Biophysical proof of target engagement:





BAY-805 is highly potent in both biochemical assays and shows high binding affinity in SPR



USP21 Probe BAY-805



Negative Control BAY-728



Probe Name	<u>BAY-805</u> (Probe)	<u>BAY-728</u> (Negative Control)
hUSP21 (HTRF) IC ₅₀ [nM]	6	12600
hUSP21 (Ub-Rhodamine) IC ₅₀ [nM]	2	16200
hUSP2 (Ub-Rhodamine) IC ₅₀ [nM]	>25000	>25000
SPR K _d [nM]	2.2	8686

USP21 Probe BAY-805


Cellular Target Engagement - USP21 HiBit CETSA Design



USP21 Probe BAY-805


Cellular Target Engagement - USP21 HiBit CETSA

C-HiBit USP21 + Compounds




	BAY-805	BAY-728
T_m	50.22	46.06

C-tag USP21-HiBit + BAY-805 @49C



EC₅₀ 0.09457

C-tag USP21-HiBit + BAY-728 @49C





Experimental Setup: HEK293T cells transfected with HiBit constructs, the next day HEK293T cells were treated with compound for 1h @37C and heated for 3 min at indicated temperatures. LgBit solution followed by substrate were then added and luciferase signal measured. Technical quadruplicates.

Cellular USP21 target engagement for BAY-805 was shown by USP21 HiBit CETSA (EC₅₀ ~ 95 nM)

USP21 Probe BAY-805






Cellular Activity in NFκB Reporter Assay



BAY-805 induces NFκB activation in a cell-based reporter assay ($EC_{50} \sim 17 \text{ nM}$)

USP21 Probe BAY-805

Selectivity Profile – USP Selectivity at SGC



BAY-805 displays very high selectivity against 9 USPs in the SGC DUB panel



USP21 Probe BAY-805

Selectivity Profile – DUB_{profiler}TM (Ubiquigent)

DUB Target	Conc.	Activity (%)
USP1/UAF1	10 µM	111
USP2	10 µM	102
USP4	10 µM	103
USP5	10 µM	110
USP5 (+Ubiquitin @ Kd)	10 µM	110
USP5 (+Ubiquitin @ Bmax)	10 µM	101
USP6	10 µM	102
USP7	10 µM	100
USP8	10 µM	96
USP9x	10 µM	108
USP11	10 µM	115
USP12/UAF1/WDR20	10 µM	91
USP14 (Proteasome-VS @ Kd)	10 µM	98
USP15	10 µM	113
USP16	10 µM	98
USP17	10 µM	97
USP19	10 µM	101

DUB Target	Conc.	Activity (%)
USP20	10 µM	87
USP21	10 µM	9
USP25	10 µM	116
USP27x	10 µM	108
USP28	10 µM	102
USP30	10 µM	97
USP35	10 µM	105
USP36	10 µM	101
USP45	10 µM	96
USP46/UAF1/WDR20	10 µM	97
CYLD	10 µM	102
UCHL1	10 µM	114
UCHL3	10 µM	101
UCHL5	10 µM	98
BAP1	10 µM	106
OTU1	10 µM	104
OTUB2	10 µM	95

DUB Target	Conc.	Activity (%)
OTUD1	10 µM	99
OTUD3	10 µM	101
OTUD5 (p117S)	10 µM	90
OTUD6A	10 µM	99
OTUD6B	10 µM	92
Cezanne	10 µM	99
VCPIP	10 µM	114
AMSH-LP	10 µM	101
AMSH-LP (+Zinc)	10 µM	93
Ataxin3	10 µM	106
Ataxin3L	10 µM	111
JOSD1	10 µM	101
JOSD2	10 µM	113



USP21 Probe BAY-805

Selectivity Profile – Eurofins Safety Screen

Assay Name	Conc.	% Inh.	Assay Name	Conc.	% Inh.
Aldose Reductase	10 µM	0	Cannabinoid CB ₁	10 µM	8
ATPase, Na ⁺ /K ⁺ , Heart, Pig	10 µM	-1	Cannabinoid CB ₂	10 µM	1
Carbonic Anhydrase II	10 µM	3	Dopamine D ₁	10 µM	-3
Cholinesterase, Acetyl, ACES	10 µM	72	Dopamine D _{2L}	10 µM	8
Cyclooxygenase COX-1	10 µM	-2	Dopamine D _{2S}	10 µM	24
Cyclooxygenase COX-2	10 µM	2	Dopamine D ₃	10 µM	9
HMG-CoA Reductase	10 µM	16	Endothelin ET _A	10 µM	-7
Leukotriene LTC ₄ Synthase	10 µM	35	Endothelin ET _B	10 µM	4
Lipoxygenase 15-LO	10 µM	-3	Estrogen ER α	10 µM	-6
Monoamine Oxidase MAO-A	10 µM	3	GABA _A , Chloride Channel, TBOB	10 µM	9
Monoamine Oxidase MAO-B	10 µM	7	GABA _A , Flunitrazepam, Central	10 µM	-7
Nitric Oxide Synthase, Neuronal (nNOS)	10 µM	-15	GABA _A , Non-Selective	10 µM	-2
Nitric Oxide Synthetase, Inducible (iNOS)	10 µM	-1	Glucocorticoid	10 µM	14
Peptidase, Angiotensin Converting Enzyme	10 µM	-33	Glutamate, AMPA	10 µM	2
Phosphodiesterase PDE3A	10 µM	3	Glutamate, Kainate	10 µM	-7
Phosphodiesterase PDE4D2	10 µM	1	Glutamate, NMDA, Agonism	10 µM	7
Phosphodiesterase PDE5A	10 µM	13	Glutamate, NMDA, Glycine	10 µM	6
Thromboxane Synthase	10 µM	-1	Growth Hormone Secretagogue (GHS, Ghrelin)	10 µM	20
Adenosine A ₁	10 µM	4	Histamine H ₁	10 µM	-1
Adenosine A _{2A}	10 µM	2	Histamine H ₂	10 µM	-16
Adenosine A ₃	10 µM	12	Histamine H ₃	10 µM	-2
Adrenergic α _{1A}	10 µM	1	Insulin	10 µM	10
Adrenergic α _{2A}	10 µM	13	Motilin	10 µM	10
Adrenergic α _{2B}	10 µM	4	Muscarinic M ₁	10 µM	18
Adrenergic α _{2C}	10 µM	6	Muscarinic M ₂	10 µM	2
Adrenergic β ₁	10 µM	3	Muscarinic M ₃	10 µM	7
Adrenergic β ₂	10 µM	3	Muscarinic M ₄	10 µM	-4
Adrenergic β ₃	10 µM	10	Nicotinic Acetylcholine α 3 β 4	10 µM	-3
Androgen (Testosterone)	10 µM	4	Opiate δ ₁ (OP1, DOP)	10 µM	-5
Angiotensin AT ₁	10 µM	14	Opiate κ (OP2, KOP)	10 µM	6
Angiotensin AT ₂	10 µM	-3	Opiate μ (OP3, MOP)	10 µM	-1
Bradykinin B ₁	10 µM	6	Progesterone PR-B	10 µM	5
Bradykinin B ₂	10 µM	-7	Purinergic P2X	10 µM	-4
			Purinergic P2Y, Non-Selective	10 µM	5

Assay Name	Conc.	% Inh.
Serotonin (5-Hydroxytryptamine) 5-HT _{1A}	10 µM	2
Serotonin (5-Hydroxytryptamine) 5-HT _{2A}	10 µM	4
Serotonin (5-Hydroxytryptamine) 5-HT _{2B}	10 µM	3
Serotonin (5-Hydroxytryptamine) 5-HT _{2C}	10 µM	-5
Transporter, Adenosine	10 µM	62
Transporter, Dopamine (DAT)	10 µM	9
Transporter, GABA	10 µM	14
Transporter, Norepinephrine (NET)	10 µM	10
Transporter, Serotonin (5-Hydroxytryptamine) (SERT)	10 µM	13
Vasopressin V _{1A}	10 µM	2

Inhibition >50% at 10 µM compound concentration for the following targets:

Assay Name	Species	Conc.	% Inh.
Cholinesterase, Acetyl, ACES	hum	10 µM	72
Transporter, Adenosine	hum	10 µM	62


Cholinesterase, Acetyl, ACES: IC₅₀ = 7.61 µM

BAY-805 shows good off-target selectivity



USP21 Probe BAY-805

Technical *in vitro* Profile



Potency

hUSP21 (HTRF) IC ₅₀ [nM]	6
hUSP21 (Ub-Rhod) IC ₅₀ [nM]	2
SPR K _d [nM]	2.2
USP21 HiBiT CETSA IC ₅₀ @ 49°C [nM]	95
Cell-based NFκB activation EC ₅₀ [nM]	17

Properties & Physchem

LogD @ pH 7.5 / LLE	3.6 / 5.1
MW / MW corr / TPSA [Å ²]	508 / 466 / 108
Solubility @ pH 6.5 [μmol/L]	3.37
Stability (pH 1/7/10, 24h, 37°C) [%]	100 / 100 / 100
Stability (r / h plasma, 4h, 37°C) [%]	99 / 99

in vitro DMPK Properties

Caco2 Permeability	P _{app} (A-B) [nm/s]		P _{app} (B-A) [nm/s]		efflux ratio	
	42		27		0.6	
metabolic stability			CL [L/h/kg]		F _{max} [%]	
	liver mics (m / r / d / h)		n.d.		n.d.	
	rat hepatocytes		3.8		10	
	human hepatocytes		n.d.		n.d.	
CYP inhibition IC ₅₀ [μM]	1A2	2C8	2C9	2D6	3A4	3A4 preinc.
	>5	4.7	>5	4.6	0.4	0.41
PXR	n.d.					

Selectivity

USP panel at SGC*	>50% remaining activity @ 10 μM (9 USPs)
Cysteine protease panel	IC ₅₀ >20 μM (6 proteases)
In-house kinase panel	IC ₅₀ >20 μM (21 kinases)

Antiproliferative Activity (human tumor cell lines)


Jurkat, Molm13, A549	all IC ₅₀ > 30 μM
MDA-MB-231, U2OS	

- BAY-805 has high *in vitro* potency and good selectivity
- BAY-805 induces NFκB activation in a cell-based reporter assay



USP21 Probe BAY-805

In vitro profile of Negative Control BAY-728



Potency	
hUSP21 (HTRF) IC ₅₀ [nM]	12600
hUSP21 (Ub-Rhod) IC ₅₀ [nM]	16200
SPR K _d [nM]	8686
USP21 HiBiT CETSA IC ₅₀ @ 49°C [nM]	-
Cell-based NfκB activation IC ₅₀ [nM]	>10000

Properties & Physchem	
LogD @ pH 7.5	3.64
MW / MW corr / TPSA [Å ²]	508 / 466 / 108
Solubility @ pH 6.5 [μmol/L]	2.88
Stability (pH 1/7/10, 24h, 37°C) [%]	100 / 99 / 100
Stability (r / h plasma, 4h, 37°C) [%]	100 / 100

in vitro DMPK Properties

Caco2 Permeability	P _{app} (A-B) [nm/s]		P _{app} (B-A) [nm/s]		efflux ratio	
	107		76		0.7	
metabolic stability			CL [L/h/kg]		F _{max} [%]	
	liver mics (m / r / d / h)		n.d.		n.d.	
	rat hepatocytes		3.0		28	
	human hepatocytes		n.d.		n.d.	
CYP inhibition IC ₅₀ [μM]	1A2	2C8	2C9	2D6	3A4	3A4 preinc.
	>5	>5	>5	>5	0.46	0.53
PXR	n.d.					

Selectivity

USP panel at SGC*	>40% remaining activity @ 10 μM (10 USPs)
Cysteine protease panel	IC ₅₀ >20 μM (6 proteases)
In-house kinase panel	IC ₅₀ >20 μM (21 kinases)

Antiproliferative Activity (human tumor cell lines)

Jurkat, Molm13, A549	all IC ₅₀ > 30 μM
MDA-MB-231, U2OS	

BAY-728 is 2100-fold (HTRF) and 8100-fold (Ub-Rhod) less potent compared to BAY-805; BAY-728 does not induce NFκB activation in a cell-based reporter assay at 10 μM



USP21 Probe BAY-805

Summary / Conclusion


Probe criteria	
Inhibitor/agonist potency: goal is < 100 nM (IC ₅₀ , K _d)	Surpasses criteria ; biochemical assays: hUSP21 (HTRF) IC ₅₀ = 6 nM, hUSP21 (Ub-Rhod) IC ₅₀ = 2 nM, SPR K _d = 2.2 nM
Selectivity within target family: goal is > 30-fold	Surpasses criteria ; good selectivity within DUB family, >50% remaining DUB activity at 10 μM for 9 other USPs
Selectivity outside target family: describe the off-targets (which may include both binding and functional data)	Surpasses criteria ; IC ₅₀ >20 μM for 21 tested inhouse kinases and 6 tested cysteine proteases, good selectivity in Eurofins Safety Screen
On target cell activity for cell-based targets: goal is < 1 μM IC ₅₀ /EC ₅₀	Surpasses criteria ; cellular activity in NFκB reporter assay with EC ₅₀ at 17 nM, cellular target engagement shown with USP21 HiBiT CETSA
Recommended cell assay concentration	use at concentration of 1 μM for BAY-805, use with control for best interpretation of data
Neg ctrl: <i>in vitro</i> potency – > 100 times less; Cell activity – >100 times less potent than the probe	Surpasses criteria ; BAY-728 is 2100- fold (HTRF) and 8100-fold (Ub-Rhod) less potent compared to BAY-805, BAY-728 does not induce NFκB activation at 10 μM

We ask for acceptance of USP21 inhibitor BAY-805 as chemical probe, accompanied by less active enantiomer BAY-728 as negative control.



USP21 Probe BAY-805

Summary / Conclusion





USP21 Probe BAY-805

Project Team / Acknowledgement

Bayer

Kirstin Petersen

Fabian Göricke

Gerd Wohlfahrt

Cora Scholten

Dennis Kirchhoff

Stefan Gradl

Markus Follmann

Niels Lindner

Hartmut Beck

Nuvisan ICB

Norbert Schmees

Jan Naujoks

Tamara Kanashova

Raphael Böhm

Namik Akkilic

Martina Schäfer

Ulrike Scheib

Ulf Bömer

Jörg Weiske

Barbara Nicke

Strutural Genomics Consortium Toronto

Victoria Vu

Masoud Vedadi

Santha Santhakumar

Cheryl Arrowsmith

Dalia Barsyte-Lovejoy

Leanna Smith

Suzanne Ackloo

Levon Halabelian

Peter Brown

Thank you to the whole team!








Thank You



USP21 Probe BAY-805

Negative Control BAY-728 – USP Selectivity at SGC





USP21 Probe BAY-805

Negative Control BAY-728 – DUBprofiler™ (Ubiquigent)

DUB Target	Conc.	Activity (%)
USP1/UAF1	10 µM	97
USP2	10 µM	82
USP4	10 µM	94
USP5	10 µM	105
USP5 (+Ubiquitin @ Kd)	10 µM	90
USP5 (+Ubiquitin @ Bmax)	10 µM	101
USP6	10 µM	105
USP7	10 µM	87
USP8	10 µM	109
USP9x	10 µM	99
USP11	10 µM	102
USP12/UAF1/WDR20	10 µM	106
USP14 (Proteasome-VS @ Kd)	10 µM	112
USP15	10 µM	105
USP16	10 µM	107
USP17	10 µM	88
USP19	10 µM	96

DUB Target	Conc.	Activity (%)
USP20	10 µM	113
USP21	10 µM	40
USP25	10 µM	105
USP27x	10 µM	96
USP28	10 µM	106
USP30	10 µM	103
USP35	10 µM	110
USP36	10 µM	95
USP45	10 µM	98
USP46/UAF1/WDR20	10 µM	100
CYLD	10 µM	100
UCHL1	10 µM	103
UCHL3	10 µM	106
UCHL5	10 µM	147
BAP1	10 µM	92.4
OTU1	10 µM	113
OTUB2	10 µM	101

DUB Target	Conc.	Activity (%)
OTUD1	10 µM	104
OTUD3	10 µM	100
OTUD5 (p117S)	10 µM	121
OTUD6A	10 µM	105
OTUD6B	10 µM	100
Cezanne	10 µM	93
VCPIP	10 µM	115
AMSH-LP	10 µM	88
AMSH-LP (+Zinc)	10 µM	107
Ataxin3	10 µM	90
Ataxin3L	10 µM	106
JOSD1	10 µM	99
JOSD2	10 µM	110



USP21 Probe BAY-805

Selectivity Profile for Negative Control BAY-728 – Eurofins Safety Screen

Assay Name	Conc.	% Inh.
Aldose Reductase	10 µM	2
ATPase, Na ⁺ /K ⁺ , Heart, Pig	10 µM	-3
Carbonic Anhydrase II	10 µM	1
Cholinesterase, Acetyl, ACES	10 µM	75
Cyclooxygenase COX-1	10 µM	3
Cyclooxygenase COX-2	10 µM	5
HMG-CoA Reductase	10 µM	1
Leukotriene LTC ₄ Synthase	10 µM	5
Lipoxygenase 15-LO	10 µM	-3
Monoamine Oxidase MAO-A	10 µM	5
Monoamine Oxidase MAO-B	10 µM	5
Nitric Oxide Synthase, Neuronal (nNOS)	10 µM	-5
Nitric Oxide Synthetase, Inducible (iNOS)	10 µM	0
Peptidase, Angiotensin Converting Enzyme	10 µM	-28
Phosphodiesterase PDE3A	10 µM	4
Phosphodiesterase PDE4D2	10 µM	1
Phosphodiesterase PDE5A	10 µM	27
Thromboxane Synthase	10 µM	15
Adenosine A ₁	10 µM	-2
Adenosine A _{2A}	10 µM	3
Adenosine A ₃	10 µM	24
Adrenergic α _{1A}	10 µM	13
Adrenergic α _{2A}	10 µM	13
Adrenergic α _{2B}	10 µM	1
Adrenergic α _{2C}	10 µM	12
Adrenergic β ₁	10 µM	4
Adrenergic β ₂	10 µM	6
Adrenergic β ₃	10 µM	8
Androgen (Testosterone)	10 µM	7
Angiotensin AT ₁	10 µM	27
Angiotensin AT ₂	10 µM	-2
Bradykinin B ₁	10 µM	23
Bradykinin B ₂	10 µM	-7

Assay Name	Conc.	% Inh.
Cannabinoid CB ₁	10 µM	3
Cannabinoid CB ₂	10 µM	4
Dopamine D ₁	10 µM	2
Dopamine D _{2L}	10 µM	17
Dopamine D _{2S}	10 µM	25
Dopamine D ₃	10 µM	2
Endothelin ET _A	10 µM	7
Endothelin ET _B	10 µM	29
Estrogen ERα	10 µM	-15
GABA _A , Chloride Channel, TBOB	10 µM	14
GABA _A , Flunitrazepam, Central	10 µM	-10
GABA _B , Non-Selective	10 µM	-1
Glucocorticoid	10 µM	43
Glutamate, AMPA	10 µM	-21
Glutamate, Kainate	10 µM	-5
Glutamate, NMDA, Agonism	10 µM	5
Glutamate, NMDA, Glycine	10 µM	19
Growth Hormone Secretagogue (GHS, Ghrelin)	10 µM	8
Histamine H ₁	10 µM	5
Histamine H ₂	10 µM	0
Histamine H ₃	10 µM	2
Insulin	10 µM	-5
Motilin	10 µM	4
Muscarinic M ₁	10 µM	36
Muscarinic M ₂	10 µM	24
Muscarinic M ₃	10 µM	4
Muscarinic M ₄	10 µM	-8
Nicotinic Acetylcholine α3β4	10 µM	-1
Opiate δ ₁ (OP1, DOP)	10 µM	5
Opiate κ (OP2, KOP)	10 µM	12
Opiate μ (OP3, MOP)	10 µM	-3
Progesterone PR-B	10 µM	16
Purinerbic P2X	10 µM	3
Purinerbic P2Y, Non-Selective	10 µM	22

Assay Name	Conc.	% Inh.
Serotonin (5-Hydroxytryptamine) 5-HT _{1A}	10 µM	5
Serotonin (5-Hydroxytryptamine) 5-HT _{2A}	10 µM	2
Serotonin (5-Hydroxytryptamine) 5-HT _{2B}	10 µM	2
Serotonin (5-Hydroxytryptamine) 5-HT _{2C}	10 µM	14
Transporter, Adenosine	10 µM	43
Transporter, Dopamine (DAT)	10 µM	41
Transporter, GABA	10 µM	23
Transporter, Norepinephrine (NET)	10 µM	37
Transporter, Serotonin (5-Hydroxytryptamine) (SERT)	10 µM	11
Vasopressin V _{1A}	10 µM	5

Inhibition >50% at 10 µM compound concentration for the following targets:

Assay Name	Species	Conc.	% Inh.
Cholinesterase, Acetyl, ACES	hum	10 µM	75


Cholinesterasem Acetyl, ACES: IC₅₀ = 6.87 µM

BAY-728 shows good off-target selectivity



USP21 Probe BAY-805

Chemical Synthesis of BAY-805



Reagents and conditions:

(a) TFA, rt; (b) HATU, DIPEA, DMF, rt;

(c) 4N HCl in dioxane, rt;


(d) 1-(trifluoromethyl)cyclohexane-1-carboxylic acid, EDC·HCl, HOBT H₂O, DIPEA, DMF, rt.

BAY-805 was synthesized in a linear sequence of 4 steps



USP21 Probe BAY-805

Chemical Synthesis of Negative Control BAY-728



Reagents and conditions:

(a) TFA, rt; (b) HATU, DIPEA, DMF, rt;

(c) 4N HCl in dioxane, rt;

(d) 1-(trifluoromethyl)cyclohexane-1-carboxylic acid, EDC·HCl, HOBT H₂O, DIPEA, DMF, rt.


BAY-728 was synthesized in a linear sequence of 4 steps



USP21 Probe BAY-805


SPR

Multicycle Mode



BAY-805 has a very slow off-rate in multicycle mode

Single Cycle Mode



K_d [nM]	k_a (1/Ms)	k_d (1/s)
$2,2 \pm 0,9$	$2,19E5 \pm 6,63E4$	$4,46E-4 \pm 2,82E-5$